

LEADERS' ROUNDTABLE ON THE FUTURE OF GENOMICS IN CANADA

OCT 21, 2021 - 3RD ROUNDTABLE



WELCOME!
CALLING FROM THE LAND OF THE ALGONQUIN ANISHINAABEG PEOPLE
REFLECT & LEARN ABOUT THE LAND YOU ARE ON TODAY

... A TIME FOR TRULY OPEN COMMUNICATION
BE GENEROUS WITH YOUR SHARING TODAY...



OUR DIVERSITY OF KNOWLEDGE IS OUR GREATEST STRENGTH

DECODING THE GENOME FOR LIFE CHANGING THERAPIES



WE HAVE AN AWESOME TEAM

OUR DIVERSITY OF KNOWLEDGE IS OUR GREATEST STRENGTH

QUESTIONS - COMMERCIAL VIABILITY

QUESTIONS - COMMERCIAL VIABILITY



ON TRANSLATION PARTI CELLARLI
SBOs (SINGLE BLOODING ALL GENE/CELL TYPES)

KEY QUESTIONS:

1. WHAT DATASETS SHOULD BE PRIORITIZED?
2. WHAT ENTITIES CAN PRODUCE VALUABLE SEQUENCING DATA (E.G. CANPAT)?
3. HOW SHOULD WE DIRECT PRIVATE-PUBLIC EFFORTS?
4. HOW CAN WE OBTAIN DIRECT INPUT FROM INDUSTRY?


THE MORE DATA, THE BETTER AI!

ALL IN A DAYS WORK!

Q & A

LARGE SHAREABLE COHORT DATASETS - STRATEGY TO ACQUIRE?

CHOOSE ONE DATASET ON 1 THERAPY SUB-TYPE
ID HOW MANY GENOMES YOU NEED




ALL DATA SETS X X X
DON'T TRY TO ANALYZE EVERYTHING X X X

PUBLIC PRIVATE

ITERATE
ITERATE
ITERATE

EPIGENETICS
MORE COMPLEX TO UNDERSTAND & ANALYZE



Q & A CONTINUED...

WHAT ABOUT AGRICULTURE?
HUGE POTENTIAL
FOOD: HEALTH
AWARENESS/ MARKETING/ BRANDING CONSIDERATIONS



YOUR WORK MAY HOLD LIFE CHANGING KNOWLEDGE
YOU NEED TO MAKE IT HAPPEN
OTHERWISE A GREAT DISCOVERY MAY DIE IN YOUR LAB...

CONSIDER STARTING A STARTUP!